0000899243-20-006853.txt : 20200303 0000899243-20-006853.hdr.sgml : 20200303 20200303203723 ACCESSION NUMBER: 0000899243-20-006853 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200228 FILED AS OF DATE: 20200303 DATE AS OF CHANGE: 20200303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dallas Jayson Donald Alexander CENTRAL INDEX KEY: 0001650322 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37519 FILM NUMBER: 20685312 MAIL ADDRESS: STREET 1: AIMMUNE THERAPEUTICS, INC. STREET 2: 8000 MARINA BOULEVARD, SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc. CENTRAL INDEX KEY: 0001631650 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452748244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 BUSINESS PHONE: (650) 614-5220 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 FORMER COMPANY: FORMER CONFORMED NAME: Allergen Research Corp DATE OF NAME CHANGE: 20150123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-28 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001650322 Dallas Jayson Donald Alexander AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005-1884 1 1 0 0 President and CEO Common Stock, $0.0001 par value 2020-02-28 4 A 0 33000 0.00 A 123699 D Stock Option (right to buy) 23.81 2020-02-28 4 A 0 200000 0.00 A 2030-02-28 Common Stock 200000 200000 D These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Includes 35,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Includes 60,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. /s/ Douglas T. Sheehy, as Attorney-in-Fact for Jayson Donald Alexander Dallas 2020-03-03